Review and update of benign prostatic hyperplasia in general practice

Area of Science:

• Urology
• Primary Care Medicine

Background:

• Benign prostatic hyperplasia (BPH) is the most common benign tumor affecting men.
• Most men with BPH initially receive assessment and management from a general practitioner (GP) in primary care.
• While urologists manage advanced cases, GPs play a vital role in the initial stages of BPH care.

Purpose of the Study:

• To outline the key principles of BPH pathogenesis.
• To describe the presentation and assessment of BPH within a primary care context.
• To review current management strategies for BPH in primary care settings.

Main Methods:

• Literature review focusing on BPH pathogenesis, clinical presentation, diagnostic approaches, and therapeutic options.
• Analysis of recent changes in pharmaceutical agents and surgical interventions for BPH.
• Emphasis on the GP's role in primary care management and referral criteria.

Main Results:

• BPH management occurred in approximately 228,000 Australian GP visits annually between 2009-2011.
• Significant advancements in BPH treatments have emerged over the last decade.
• GPs require updated knowledge on BPH assessment and management, including new therapies and referral guidelines.

Conclusions:

• GPs are integral to the primary care management of benign prostatic hyperplasia.
• Continuous education for GPs on BPH is necessary due to evolving treatment landscapes.
• Clear understanding of when to refer patients to a urologist is critical for optimal BPH patient outcomes.